{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:29Z","timestamp":1792783349313,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Firenze","id":[{"id":"https:\/\/ror.org\/04jr1s763","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The epidemiology of hepatocellular carcinoma (HCC) is increasingly shaped by the expanding burden of type 2 diabetes (T2D), obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed as glucose-lowering agents, have emerged as systemic metabolic therapies with effects extending beyond glycemic control, including weight reduction, cardiovascular and renal protection, and improvement of steatotic liver disease. This review summarizes current evidence on the potential role of GLP-1RAs in modifying the natural history of MASLD and reducing HCC risk. Clinical trials consistently support beneficial effects on steatosis and metabolic dysfunction-associated steatohepatitis, particularly in non-cirrhotic patients, whereas effects in established cirrhosis appear less consistent. Real-world studies and target trial emulations suggest that GLP-1RA use may be associated with lower rates of hepatic decompensation, cirrhosis progression, and incident HCC, although the magnitude and robustness of these associations vary according to disease stage, comparator therapy, exposure definition, and outcome hierarchy. The strongest apparent benefit is generally observed against insulin or sulfonylureas, while differences are attenuated in comparisons with other metabolically favorable agents, such as SGLT2 inhibitors. Mechanistic data support indirect hepatoprotective actions mediated by reduced insulin resistance, lipotoxicity, inflammation, fibrogenesis, adipose\u2013liver crosstalk, and tumor-promoting pathways. Overall, GLP-1RAs represent promising disease-modifying agents in metabolic liver disease, but dedicated prospective studies are required to establish causality and define their role in HCC prevention.<\/jats:p>","DOI":"10.1007\/s11739-026-04456-1","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:02:38Z","timestamp":1785258158000},"page":"2443-2465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma"],"prefix":"10.1007","volume":"21","author":[{"given":"Alfredo","family":"Vozza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Vizzutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8629-0878","authenticated-orcid":false,"given":"Fabio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"6","key":"4456_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2020","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J et al (2020) Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 77(6):1598\u20131606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021","journal-title":"J Hepatol"},{"issue":"5","key":"4456_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/jcag\/gwae025","volume":"7","author":"F Jaber","year":"2024","unstructured":"Jaber F, Cholankeril G, El-Serag HB (2024) Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies. J Can Assoc Gastroenterol 7(5):331\u2013345. https:\/\/doi.org\/10.1093\/jcag\/gwae025","journal-title":"J Can Assoc Gastroenterol"},{"issue":"1","key":"4456_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-06617-2","volume":"15","author":"J Tang","year":"1990","unstructured":"Tang J, Yang R, Li K, Peng W, He Z, Gao W et al (1990) Trends and future projections of liver cancer attributable to metabolic dysfunction-associated steatohepatitis in China from 1990 to 2050. Sci Rep 15(1):23255. https:\/\/doi.org\/10.1038\/s41598-025-06617-2","journal-title":"Sci Rep"},{"issue":"11","key":"4456_CR4","doi-asserted-by":"publisher","first-page":"e2445525","DOI":"10.1001\/jamanetworkopen.2024.45525","volume":"7","author":"S Qiu","year":"2040","unstructured":"Qiu S, Cai J, Yang Z, He X, Xing Z, Zu J et al (2040) Trends in hepatocellular carcinoma mortality rates in the US and projections through 2040. JAMA Netw Open 7(11):e2445525. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.45525","journal-title":"JAMA Netw Open"},{"issue":"10","key":"4456_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R et al (2024) The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol 22(10):1999-2010.e8. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"4456_CR6","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/HEP.0000000000001211","volume":"82","author":"A Unalp-Arida","year":"2025","unstructured":"Unalp-Arida A, Ruhl CE (2025) Prevalence of metabolic dysfunction\u2013associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data. Hepatology 82(5):1256\u20131273. https:\/\/doi.org\/10.1097\/HEP.0000000000001211","journal-title":"Hepatology"},{"issue":"3","key":"4456_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","volume":"4","author":"HB El\u2013Serag","year":"2006","unstructured":"El\u2013Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4(3):369\u2013380. https:\/\/doi.org\/10.1016\/j.cgh.2005.12.007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"4456_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/atm.2017.04.41","volume":"5","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Targher G (2017) Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med 5(13):270\u2013270. https:\/\/doi.org\/10.21037\/atm.2017.04.41","journal-title":"Ann Transl Med"},{"issue":"3","key":"4456_CR9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s12072-023-10498-w","volume":"17","author":"T Prabhakar","year":"2023","unstructured":"Prabhakar T, Kaushal K, Prasad M, Gupta E, Sood A, Jain AK et al (2023) Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study. Hepatol Int 17(3):745\u2013752. https:\/\/doi.org\/10.1007\/s12072-023-10498-w","journal-title":"Hepatol Int"},{"issue":"7","key":"4456_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/apt.14937","volume":"48","author":"JG Stine","year":"2018","unstructured":"Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH et al (2018) Systematic review with meta\u2010analysis: risk of hepatocellular carcinoma in non\u2010alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 48(7):696\u2013703. https:\/\/doi.org\/10.1111\/apt.14937","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"4456_CR11","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1111\/liv.16016","volume":"44","author":"DR Riley","year":"2024","unstructured":"Riley DR, Hydes T, Hernadez G, Zhao SS, Alam U, Cuthbertson DJ (2024) The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes\u2010related and cancer outcomes. Liver Int 44(10):2538\u20132550. https:\/\/doi.org\/10.1111\/liv.16016","journal-title":"Liver Int"},{"issue":"7","key":"4456_CR12","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D et al (2025) Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care 48(7):1057\u20131082. https:\/\/doi.org\/10.2337\/dci24-0094","journal-title":"Diabetes Care"},{"issue":"6","key":"4456_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R et al (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"issue":"1","key":"4456_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01366-8","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G et al (2021) GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol 20(1):189. https:\/\/doi.org\/10.1186\/s12933-021-01366-8","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"4456_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT et al (2025) Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 13(1):15\u201328. https:\/\/doi.org\/10.1016\/S2213-8587(24)00271-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"4456_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70000","volume":"55","author":"A Pasta","year":"2025","unstructured":"Pasta A, Facciorusso A, Plaz Torres MC, Giannini EG, Sacco R (2025) Effects of glucagon\u2010like PEPTIDE\u20101 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: a systematic review and META\u2010analysis. Eur J Clin Invest 55(6):e70000. https:\/\/doi.org\/10.1111\/eci.70000","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"4456_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/13543784.2025.2473062","volume":"34","author":"N Alkhouri","year":"2025","unstructured":"Alkhouri N, Charlton M, Gray M, Noureddin M (2025) The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists. Expert Opin Investig Drugs 34(3):169\u2013195. https:\/\/doi.org\/10.1080\/13543784.2025.2473062","journal-title":"Expert Opin Investig Drugs"},{"key":"4456_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112407","volume":"227","author":"WM Chen","year":"2025","unstructured":"Chen WM, Ng HJ, Jao AT, Wu SY, Soong RS (2025) GLP-1 receptor agonists and risk of hepatocellular carcinoma and all-cause mortality in patients with MASLD and type 2 diabetes: a propensity score\u2013matched population-based cohort study. Diabetes Res Clin Pract 227:112407. https:\/\/doi.org\/10.1016\/j.diabres.2025.112407","journal-title":"Diabetes Res Clin Pract"},{"issue":"21","key":"4456_CR19","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS et al (2025) Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis. N Engl J Med 392(21):2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"issue":"6","key":"4456_CR20","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78(6):1966\u20131986. https:\/\/doi.org\/10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"issue":"1","key":"4456_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C et al (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4456_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27(4):740\u2013756. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"issue":"3","key":"4456_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, Ratziu V, Bugianesi E, Francque S et al (2024) EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"issue":"2","key":"4456_CR24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","volume":"68","author":"F Marra","year":"2018","unstructured":"Marra F, Svegliati-Baroni G (2018) Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 68(2):280\u2013295. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.014","journal-title":"J Hepatol"},{"issue":"10","key":"4456_CR25","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI (2021) Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184(10):2537\u20132564. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015","journal-title":"Cell"},{"issue":"10019","key":"4456_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"issue":"12","key":"4456_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384(12):1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"issue":"6","key":"4456_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kj\u00e6r MS, Krarup N et al (2023) Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 8(6):511\u2013522. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"4456_CR29","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","volume":"63","author":"MS Kuchay","year":"2020","unstructured":"Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS et al (2020) Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 63(11):2434\u20132445. https:\/\/doi.org\/10.1007\/s00125-020-05265-7","journal-title":"Diabetologia"},{"issue":"4","key":"4456_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","volume":"167","author":"L Wang","year":"2024","unstructured":"Wang L, Berger NA, Kaelber DC, Xu R (2024) Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology 167(4):689\u2013703. https:\/\/doi.org\/10.1053\/j.gastro.2024.04.029","journal-title":"Gastroenterology"},{"issue":"11","key":"4456_CR31","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","volume":"184","author":"F Kanwal","year":"2024","unstructured":"Kanwal F, Kramer JR, Li L, Yang YX, Cao Y, Yu X et al (2024) GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. JAMA Intern Med 184(11):1314. https:\/\/doi.org\/10.1001\/jamainternmed.2024.4661","journal-title":"JAMA Intern Med"},{"issue":"3","key":"4456_CR32","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3350\/cmh.2024.1096","volume":"31","author":"X Mao","year":"2025","unstructured":"Mao X, Zhang X, Lai R, Cheung KS, Yuen MF, Cheung R et al (2025) Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study. Clin Mol Hepatol 31(3):1084\u20131099. https:\/\/doi.org\/10.3350\/cmh.2024.1096","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"4456_CR33","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/apt.18502","volume":"61","author":"C Kuo","year":"2025","unstructured":"Kuo C, Chuang M, Li C, Tsai Y, Huang P, Kuo H et al (2025) Glucagon\u2010like peptide\u20101 receptor agonists and liver outcomes in patients with MASLD and type 2 diabetes. Aliment Pharmacol Ther 61(7):1163\u20131174. https:\/\/doi.org\/10.1111\/apt.18502","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"4456_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/jgh.16752","volume":"40","author":"PRC Passos","year":"2025","unstructured":"Passos PRC, Filho VOC, Noronha MM, Hyppolito EB, Saldanha EF, Motta RV (2025) Influence of glucagon\u2010like peptide\u20101 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta\u2010analysis. J Gastroenterol Hepatol 40(1):67\u201377. https:\/\/doi.org\/10.1111\/jgh.16752","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"4456_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/gutjnl-2023-330962","volume":"73","author":"A Wester","year":"2024","unstructured":"Wester A, Shang Y, Toresson Grip E, Matthews AA, Hagstr\u00f6m H (2024) Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes. Gut 73(5):835\u2013843. https:\/\/doi.org\/10.1136\/gutjnl-2023-330962","journal-title":"Gut"},{"issue":"2","key":"4456_CR36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/gutjnl-2024-332687","volume":"74","author":"S Bea","year":"2025","unstructured":"Bea S, Ko HY, Bae JH, Cho YM, Chang Y, Ryu S et al (2025) Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease. Gut 74(2):284\u2013294. https:\/\/doi.org\/10.1136\/gutjnl-2024-332687","journal-title":"Gut"},{"key":"4456_CR37","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2023.0814","author":"D Huynh","year":"2023","unstructured":"Huynh D (2023) Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus. Ann Gastroenterol. https:\/\/doi.org\/10.20524\/aog.2023.0814","journal-title":"Ann Gastroenterol"},{"issue":"9","key":"4456_CR38","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/apt.17925","volume":"59","author":"MI Elsaid","year":"2024","unstructured":"Elsaid MI, Li N, Firkins SA, Rustgi VK, Paskett ED, Acharya C et al (2024) Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Aliment Pharmacol Ther 59(9):1096\u20131110. https:\/\/doi.org\/10.1111\/apt.17925","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"4456_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/joim.13751","volume":"295","author":"C Yang","year":"2024","unstructured":"Yang C, Yao W, Yang C, Peng Z, Ou H, Kuo S (2024) Lower risks of cirrhosis and hepatocellular carcinoma with GLP\u20101RAs in type 2 diabetes: a nationwide cohort study using target trial emulation framework. J Intern Med 295(3):357\u2013368. https:\/\/doi.org\/10.1111\/joim.13751","journal-title":"J Intern Med"},{"issue":"4","key":"4456_CR40","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1111\/dom.70505","volume":"28","author":"J Sarker","year":"2026","unstructured":"Sarker J, Okpara E, De Los Santos B, Kim M, Kim K (2026) Comparative effectiveness of GLP\u20101 receptor agonists, SGLT2 inhibitors and DPP\u20104 inhibitors on liver outcomes in metabolic dysfunction\u2010associated steatotic liver disease: a retrospective cohort study. Diabetes Obes Metab 28(4):3155\u20133164. https:\/\/doi.org\/10.1111\/dom.70505","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"4456_CR41","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1097\/HEP.0000000000000712","volume":"79","author":"A Engstr\u00f6m","year":"2024","unstructured":"Engstr\u00f6m A, Wintzell V, Melbye M, Svanstr\u00f6m H, Eliasson B, Gudbj\u00f6rnsdottir S et al (2024) Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: a Scandinavian cohort study. Hepatology 79(6):1401\u20131411. https:\/\/doi.org\/10.1097\/HEP.0000000000000712","journal-title":"Hepatology"},{"issue":"1","key":"4456_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01775-2","volume":"24","author":"M Shabil","year":"2024","unstructured":"Shabil M, Khatib MN, Ballal S, Bansal P, Tomar BS, Ashraf A et al (2024) Risk of hepatocellular carcinoma with glucagon-like peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis. BMC Endocr Disord 24(1):246. https:\/\/doi.org\/10.1186\/s12902-024-01775-2","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"4456_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03228-4","volume":"22","author":"FS Yen","year":"2024","unstructured":"Yen FS, Hou MC, Wei JCC, Shih YH, Hwu CM, Hsu CC (2024) Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes. BMC Med 22(1):8. https:\/\/doi.org\/10.1186\/s12916-023-03228-4","journal-title":"BMC Med"},{"issue":"24","key":"4456_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71434","volume":"14","author":"A Dalbeni","year":"2025","unstructured":"Dalbeni A, Vicardi M, Natola LA, Cattazzo F, Auriemma A, Lombardi R et al (2025) Glucagon-like peptide-1 receptor agonists and hepatocellular carcinoma prevention: a meta-analysis and clinical decision framework. Cancer Med 14(24):e71434. https:\/\/doi.org\/10.1002\/cam4.71434","journal-title":"Cancer Med"},{"issue":"5","key":"4456_CR45","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/gutjnl-2024-334591","volume":"74","author":"C Celsa","year":"2025","unstructured":"Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Infantino G et al (2025) Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies. Gut 74(5):815\u2013824. https:\/\/doi.org\/10.1136\/gutjnl-2024-334591","journal-title":"Gut"},{"issue":"1","key":"4456_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101661","volume":"8","author":"L Li","year":"2026","unstructured":"Li L, Mao X, Lee CH, Wai Lui DT, Wan-Hin Hui R, Mak LY et al (2026) Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: a network meta-analysis. JHEP Rep 8(1):101661. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101661","journal-title":"JHEP Rep"},{"issue":"11","key":"4456_CR47","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.amjmed.2024.06.031","volume":"137","author":"S Xiao","year":"2024","unstructured":"Xiao S, Liu Y, Fu X, Chen T, Xie W (2024) Modifiable risk factors for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease: a meta-analysis. Am J Med 137(11):1072-1081.e32. https:\/\/doi.org\/10.1016\/j.amjmed.2024.06.031","journal-title":"Am J Med"},{"issue":"24","key":"4456_CR48","doi-asserted-by":"publisher","first-page":"11890","DOI":"10.26355\/eurrev_202312_34788","volume":"27","author":"WP Guo","year":"2023","unstructured":"Guo WP, Zhang HY, Liu LX (2023) Risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 27(24):11890\u201311903. https:\/\/doi.org\/10.26355\/eurrev_202312_34788","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"4456_CR49","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.dld.2021.12.002","volume":"54","author":"DS Nasereldin","year":"2022","unstructured":"Nasereldin DS, White LJ, Hodge DO, Roberts LR, Patel T, Antwi SO (2022) Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk. Dig Liver Dis 54(7):964\u2013972. https:\/\/doi.org\/10.1016\/j.dld.2021.12.002","journal-title":"Dig Liver Dis"},{"issue":"5","key":"4456_CR50","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/hep.29660","volume":"67","author":"TG Simon","year":"2018","unstructured":"Simon TG, King LY, Chong DQ, Nguyen LH, Ma Y, VoPham T et al (2018) Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies. Hepatology 67(5):1797\u20131806. https:\/\/doi.org\/10.1002\/hep.29660","journal-title":"Hepatology"},{"issue":"10","key":"4456_CR51","doi-asserted-by":"publisher","first-page":"1327814","DOI":"10.3389\/fnut.2023.1327814","volume":"14","author":"G Ruan","year":"2023","unstructured":"Ruan G, Wu F, Shi D, Sun H, Wang F, Xu C (2023) Metformin: update on mechanisms of action on liver diseases. Front Nutr 14(10):1327814. https:\/\/doi.org\/10.3389\/fnut.2023.1327814","journal-title":"Front Nutr"},{"key":"4456_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112918","volume":"229","author":"JY Wu","year":"2025","unstructured":"Wu JY, Chang HY, Tsung Y, Lin YM (2025) Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM. Diabetes Res Clin Pract 229:112918. https:\/\/doi.org\/10.1016\/j.diabres.2025.112918","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"4456_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101698","volume":"51","author":"RS Soong","year":"2025","unstructured":"Soong RS, Chen WM, Jao AT, Lee MC, Wu SY, Lin CL (2025) SGLT2 inhibitors and the risk of hepatocellular carcinoma in patients with MASLD and type 2 diabetes. Diabetes Metab 51(6):101698. https:\/\/doi.org\/10.1016\/j.diabet.2025.101698","journal-title":"Diabetes Metab"},{"issue":"12","key":"4456_CR54","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","volume":"73","author":"X Mao","year":"2024","unstructured":"Mao X, Zhang X, Kam L, Chien N, Lai R, Cheung KS et al (2024) Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Gut 73(12):2054\u20132061. https:\/\/doi.org\/10.1136\/gutjnl-2024-332481","journal-title":"Gut"},{"issue":"11","key":"4456_CR55","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2025.3590","volume":"160","author":"TS Barrett","year":"2025","unstructured":"Barrett TS, Hafermann JO, Richards S, LeJeune K, Eid GM (2025) Obesity treatment with bariatric surgery vs GLP-1 receptor agonists. JAMA Surg 160(11):1232. https:\/\/doi.org\/10.1001\/jamasurg.2025.3590","journal-title":"JAMA Surg"},{"issue":"6","key":"4456_CR56","doi-asserted-by":"publisher","first-page":"e2415392","DOI":"10.1001\/jamanetworkopen.2024.15392","volume":"7","author":"D Dicker","year":"2024","unstructured":"Dicker D, Sagy YW, Ramot N, Battat E, Greenland P, Arbel R et al (2024) Bariatric metabolic surgery vs glucagon-like peptide-1 receptor agonists and mortality. JAMA Netw Open 7(6):e2415392. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.15392","journal-title":"JAMA Netw Open"},{"issue":"10271","key":"4456_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","volume":"397","author":"G Mingrone","year":"2021","unstructured":"Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Capristo E et al (2021) Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. The Lancet 397(10271):293\u2013304. https:\/\/doi.org\/10.1016\/S0140-6736(20)32649-0","journal-title":"The Lancet"},{"issue":"4","key":"4456_CR58","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H et al (2020) Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 159(4):1290-1301.e5. https:\/\/doi.org\/10.1053\/j.gastro.2020.06.006","journal-title":"Gastroenterology"},{"issue":"4","key":"4456_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70075","volume":"8","author":"A Hussein","year":"2025","unstructured":"Hussein A, Awashra A, Rajab I, Bdair M, Hamdan D, Nouri A et al (2025) Comparative effectiveness of bariatric surgery versus GLP-1 receptor agonists in reducing the risk of new-onset of NASH: a retrospective multinational cohort study from North America and Europe. Endocrinol Diabetes Metab 8(4):e70075. https:\/\/doi.org\/10.1002\/edm2.70075","journal-title":"Endocrinol Diabetes Metab"},{"issue":"5","key":"4456_CR60","doi-asserted-by":"publisher","first-page":"e0949","DOI":"10.1097\/HC9.0000000000000949","volume":"10","author":"J Choi","year":"2026","unstructured":"Choi J, Mitchell G, Nguyen VH, Przybyszewski E, Song J, Carroll A et al (2026) GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes. Hepatol Commun 10(5):e0949. https:\/\/doi.org\/10.1097\/HC9.0000000000000949","journal-title":"Hepatol Commun"},{"key":"4456_CR61","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001771","author":"X Mao","year":"2026","unstructured":"Mao X, Fan H, Yuen MF, Cheung R, Seto WK, Nguyen MH (2026) GLP-1 receptor agonist\u2013SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000001771","journal-title":"Hepatology"},{"issue":"11\u201312","key":"4456_CR62","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/apt.70382","volume":"62","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Rinella M, Taub R, Labriola D, Camacho RC, Alkhouri N et al (2025) Effects of resmetirom on metabolic-dysfunction associated steatohepatitis in patients with weight loss and\/or diabetes taking glucagon-like peptide-1 receptor agonists and other diabetes therapies: a secondary analysis of the MAESTRO - NASH trial. Aliment Pharmacol Ther 62(11\u201312):1089\u20131099. https:\/\/doi.org\/10.1111\/apt.70382","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"4456_CR63","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","volume":"23","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S et al (2025) Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study. Clin Gastroenterol Hepatol 23(1):103\u2013113. https:\/\/doi.org\/10.1016\/j.cgh.2024.02.022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"4456_CR64","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E et al (2024) Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis. N Engl J Med 391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"issue":"4","key":"4456_CR65","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E et al (2024) A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 391(4):311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa2401755","journal-title":"N Engl J Med"},{"issue":"7","key":"4456_CR66","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK et al (2024) Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med 30(7):2037\u20132048. https:\/\/doi.org\/10.1038\/s41591-024-03018-2","journal-title":"Nat Med"},{"issue":"11","key":"4456_CR67","doi-asserted-by":"publisher","first-page":"e70407","DOI":"10.1111\/liv.70407","volume":"45","author":"S Petta","year":"2025","unstructured":"Petta S, Kim K, Targher G, Romeo S, Sookoian S, Zheng M et al (2025) Focus on Semaglutide 2.4 mg\/week for the Treatment of Metabolic Dysfunction\u2010Associated Steatohepatitis. Liver Int 45(11):e70407. https:\/\/doi.org\/10.1111\/liv.70407","journal-title":"Liver Int"},{"issue":"5","key":"4456_CR68","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK et al (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51(5):1584\u20131592. https:\/\/doi.org\/10.1002\/hep.23569","journal-title":"Hepatology"},{"issue":"6","key":"4456_CR69","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","volume":"54","author":"S Ben-Shlomo","year":"2011","unstructured":"Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z et al (2011) Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 54(6):1214\u20131223. https:\/\/doi.org\/10.1016\/j.jhep.2010.09.032","journal-title":"J Hepatol"},{"issue":"8","key":"4456_CR70","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s11626-017-0181-y","volume":"53","author":"AY Chen-Liaw","year":"2017","unstructured":"Chen-Liaw AY, Hammel G, Gomez G (2017) Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells. In Vitro Cell Dev Biol Anim 53(8):721\u2013727. https:\/\/doi.org\/10.1007\/s11626-017-0181-y","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"4456_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"issue":"9","key":"4456_CR72","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","volume":"31","author":"M Jara","year":"2025","unstructured":"Jara M, Norlin J, Kj\u00e6r MS, Almholt K, Bendtsen KM, Bugianesi E et al (2025) Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat Med 31(9):3128\u20133140. https:\/\/doi.org\/10.1038\/s41591-025-03799-0","journal-title":"Nat Med"},{"issue":"2","key":"4456_CR73","doi-asserted-by":"publisher","first-page":"030006052199298","DOI":"10.1177\/0300060521992981","volume":"49","author":"X Chen","year":"2021","unstructured":"Chen X, Huang Q, Feng J, Xiao Z, Zhang X, Zhao L (2021) GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-\u03baB signalling pathway. J Int Med Res 49(2):0300060521992981. https:\/\/doi.org\/10.1177\/0300060521992981","journal-title":"J Int Med Res"},{"key":"4456_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869050","volume":"13","author":"SL Li","year":"2022","unstructured":"Li SL, Wang ZM, Xu C, Che FH, Hu XF, Cao R et al (2022) Liraglutide attenuates hepatic ischemia\u2013reperfusion injury by modulating macrophage polarization. Front Immunol 13:869050. https:\/\/doi.org\/10.3389\/fimmu.2022.869050","journal-title":"Front Immunol"},{"issue":"2","key":"4456_CR75","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","volume":"64","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL et al (2016) Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 64(2):399\u2013408. https:\/\/doi.org\/10.1016\/j.jhep.2015.08.038","journal-title":"J Hepatol"},{"issue":"6","key":"4456_CR76","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.2337\/db06-1182","volume":"56","author":"YS Lee","year":"2007","unstructured":"Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J et al (2007) Glucagon-Like Peptide-1 Gene Therapy in Obese Diabetic Mice Results in Long-Term Cure of Diabetes by Improving Insulin Sensitivity and Reducing Hepatic Gluconeogenesis. Diabetes 56(6):1671\u20131679. https:\/\/doi.org\/10.2337\/db06-1182","journal-title":"Diabetes"},{"issue":"5","key":"4456_CR77","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/cts.13235","volume":"15","author":"MB M\u00f8llerh\u00f8j","year":"2022","unstructured":"M\u00f8llerh\u00f8j MB, Veidal SS, Thrane KT, Or\u00f3 D, Overgaard A, Salinas CG et al (2022) Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet\u2010induced obese and biopsy\u2010confirmed mouse model of NASH. Clin Transl Sci 15(5):1167\u20131186. https:\/\/doi.org\/10.1111\/cts.13235","journal-title":"Clin Transl Sci"},{"issue":"2","key":"4456_CR78","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1021\/acs.jproteome.3c00498","volume":"23","author":"Y Liu","year":"2024","unstructured":"Liu Y, Chen S, Zhen R (2024) Effect of semaglutide on high-fat-diet-induced liver cancer in obese mice. J Proteome Res 23(2):704\u2013717. https:\/\/doi.org\/10.1021\/acs.jproteome.3c00498","journal-title":"J Proteome Res"},{"issue":"29","key":"4456_CR79","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1038\/onc.2017.38","volume":"36","author":"M Zhou","year":"2017","unstructured":"Zhou M, Mok MTS, Sun H, Chan AW, Huang Y, Cheng ASL et al (2017) The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP\u2013PKA\u2013EGFR\u2013STAT3 axis. Oncogene 36(29):4135\u20134149. https:\/\/doi.org\/10.1038\/onc.2017.38","journal-title":"Oncogene"},{"issue":"16","key":"4456_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165722","volume":"21","author":"M Kojima","year":"2020","unstructured":"Kojima M, Takahashi H, Kuwashiro T, Tanaka K, Mori H, Ozaki I et al (2020) Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis. Int J Mol Sci 21(16):5722. https:\/\/doi.org\/10.3390\/ijms21165722","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4456_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100872","volume":"14","author":"X Lu","year":"2021","unstructured":"Lu X, Xu C, Dong J, Zuo S, Zhang H, Jiang C et al (2021) Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6\/STAT3 signaling in hepatocellular carcinoma. Transl Oncol 14(1):100872. https:\/\/doi.org\/10.1016\/j.tranon.2020.100872","journal-title":"Transl Oncol"},{"key":"4456_CR82","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2017.05.015","volume":"809","author":"GC Krause","year":"2017","unstructured":"Krause GC, Lima KG, Dias HB, Da Silva EFG, Haute GV, Basso BS et al (2017) Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells. Eur J Pharmacol 809:32\u201341. https:\/\/doi.org\/10.1016\/j.ejphar.2017.05.015","journal-title":"Eur J Pharmacol"},{"key":"4456_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2021.108851","volume":"703","author":"N Yamada","year":"2021","unstructured":"Yamada N, Matsushima-Nishiwaki R, Kobayashi K, Tachi J, Kozawa O (2021) GLP-1 reduces the migration of hepatocellular carcinoma cells via suppression of the stress-activated protein kinase\/c-Jun N-terminal kinase pathway. Arch Biochem Biophys 703:108851. https:\/\/doi.org\/10.1016\/j.abb.2021.108851","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"4456_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52103-x","volume":"9","author":"MSA Madsen","year":"2019","unstructured":"Madsen MSA, Holm JB, Pallej\u00e0 A, Wismann P, Fabricius K, Rigbolt K et al (2019) Metabolic and gut microbiome changes following GLP-1 or dual GLP-1\/GLP-2 receptor agonist treatment in diet-induced obese mice. Sci Rep 9(1):15582. https:\/\/doi.org\/10.1038\/s41598-019-52103-x","journal-title":"Sci Rep"},{"issue":"1","key":"4456_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00796-5","volume":"12","author":"H Huang","year":"2020","unstructured":"Huang H, Ren Z, Gao X, Hu X, Zhou Y, Jiang J et al (2020) Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma. Genome Med 12(1):102. https:\/\/doi.org\/10.1186\/s13073-020-00796-5","journal-title":"Genome Med"},{"issue":"2","key":"4456_CR86","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jhep.2019.08.016","volume":"72","author":"RF Schwabe","year":"2020","unstructured":"Schwabe RF, Greten TF (2020) Gut microbiome in HCC \u2013 mechanisms, diagnosis and therapy. J Hepatol 72(2):230\u2013238. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.016","journal-title":"J Hepatol"},{"issue":"6494","key":"4456_CR87","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.aay9189","volume":"368","author":"D Nejman","year":"2020","unstructured":"Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT et al (2020) The human tumor microbiome is composed of tumor type\u2013specific intracellular bacteria. Science 368(6494):973\u2013980. https:\/\/doi.org\/10.1126\/science.aay9189","journal-title":"Science"},{"issue":"11","key":"4456_CR88","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","volume":"34","author":"H Tilg","year":"2022","unstructured":"Tilg H, Adolph TE, Trauner M (2022) Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab 34(11):1700\u20131718. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.017","journal-title":"Cell Metab"},{"issue":"6391","key":"4456_CR89","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5931","volume":"360","author":"C Ma","year":"2018","unstructured":"Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M et al (2018) Gut microbiome\u2013mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360(6391):eaan5931. https:\/\/doi.org\/10.1126\/science.aan5931","journal-title":"Science"},{"issue":"16","key":"4456_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17162600","volume":"17","author":"S Hanna","year":"2025","unstructured":"Hanna S, Sethiadi J, Ali Q, Sinha S (2025) Repurposing GLP-1 receptor agonists: a perspective on epigenetic strategies to combat fibrosis and hepatocellular carcinoma in the aged liver. Cancers (Basel) 17(16):2600. https:\/\/doi.org\/10.3390\/cancers17162600","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4456_CR91","doi-asserted-by":"publisher","first-page":"G652","DOI":"10.1152\/ajpgi.00221.2010","volume":"299","author":"R Kohli","year":"2010","unstructured":"Kohli R, Kirby M, Setchell KDR, Jha P, Klustaitis K, Woollett LA et al (2010) Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol-Gastrointest Liver Physiol 299(3):G652\u2013G660. https:\/\/doi.org\/10.1152\/ajpgi.00221.2010","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"issue":"1","key":"4456_CR92","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.22627","volume":"49","author":"K Song","year":"2009","unstructured":"Song K, Li T, Owsley E, Strom S, Chiang JYL (2009) Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7\u03b1\u2010hydroxylase gene expression\u2020. Hepatology 49(1):297\u2013305. https:\/\/doi.org\/10.1002\/hep.22627","journal-title":"Hepatology"},{"issue":"4","key":"4456_CR93","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/hep.29857PubMedPMID:29486523;PubMedCentralPMCID:PMC6111007","volume":"68","author":"P Pathak","year":"2018","unstructured":"Pathak P, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW et al (2018) Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatol Baltim Md 68(4):1574\u20131588. https:\/\/doi.org\/10.1002\/hep.29857PubMedPMID:29486523;PubMedCentralPMCID:PMC6111007","journal-title":"Hepatol Baltim Md"},{"issue":"11","key":"4456_CR94","doi-asserted-by":"publisher","first-page":"964","DOI":"10.14218\/JCTH.2025.00204","volume":"13","author":"JL Wang","year":"2025","unstructured":"Wang JL, Xiao Y, Li ML, Chen GL, Cui MH, Liu JL (2025) Research progress on leptin in metabolic dysfunction-associated fatty liver disease. J Clin Transl Hepatol. https:\/\/doi.org\/10.14218\/JCTH.2025.00204","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"4456_CR95","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1158\/0008-5472.CAN-06-3075PubMedPMID:17363567;PubMedCentralPMCID:PMC2925446","volume":"67","author":"NK Saxena","year":"2007","unstructured":"Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D et al (2007) Concomitant activation of the JAK\/STAT, PI3K\/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67(6):2497\u20132507. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3075PubMedPMID:17363567;PubMedCentralPMCID:PMC2925446","journal-title":"Cancer Res"},{"key":"4456_CR96","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S69004","volume":"8","author":"Q Sun","year":"2014","unstructured":"Sun Q, Jiang N, Sun R (2014) Leptin signaling molecular actions and drug target in hepatocellular carcinoma. Drug Des Devel Ther 8:2295. https:\/\/doi.org\/10.2147\/DDDT.S69004","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"4456_CR97","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.62347\/PZDM1736","volume":"14","author":"P Hu","year":"2024","unstructured":"Hu P (2024) The role of novel adipokines in hepatocellular carcinoma progression: a mini review. Am J Cancer Res 14(11):5471\u20135485. https:\/\/doi.org\/10.62347\/PZDM1736","journal-title":"Am J Cancer Res"},{"issue":"1","key":"4456_CR98","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.diabres.2014.01.019","volume":"104","author":"G D\u00edaz-Soto","year":"2014","unstructured":"D\u00edaz-Soto G, De Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E (2014) Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. Diabetes Res Clin Pract 104(1):92\u201396. https:\/\/doi.org\/10.1016\/j.diabres.2014.01.019","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"4456_CR99","doi-asserted-by":"publisher","first-page":"217","DOI":"10.14712\/fb2013059060217","volume":"59","author":"WH Feng","year":"2013","unstructured":"Feng WH, Yuan XW, Tong GY, Wang WM, Hu Y, Shen SM et al (2013) Correlated increase of omentin-1 and adiponectin by exenatide, avandamet and dietary change in diet-induced obese rats. Folia Biol (Praha) 59(6):217\u2013224. https:\/\/doi.org\/10.14712\/fb2013059060217","journal-title":"Folia Biol (Praha)"},{"issue":"10","key":"4456_CR100","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1507\/endocrj.EJ21-0802","volume":"69","author":"X Lyu","year":"2022","unstructured":"Lyu X, Yan K, Wang X, Xu H, Guo X, Zhu H et al (2022) A novel anti-obesity mechanism for liraglutide by improving adipose tissue leptin resistance in high-fat diet-fed obese mice. Endocr J 69(10):1233\u20131244. https:\/\/doi.org\/10.1507\/endocrj.EJ21-0802","journal-title":"Endocr J"},{"key":"4456_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108899","volume":"177","author":"LE Simental-Mend\u00eda","year":"2021","unstructured":"Simental-Mend\u00eda LE, S\u00e1nchez-Garc\u00eda A, Linden-Torres E, Simental-Mend\u00eda M (2021) Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 177:108899. https:\/\/doi.org\/10.1016\/j.diabres.2021.108899","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"4456_CR102","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1139\/cjpp-2017-0650","volume":"96","author":"NAT Abbas","year":"2018","unstructured":"Abbas NAT, El. Salem A (2018) Metformin, sitagliptin, and liraglutide modulate serum retinol-binding protein-4 level and adipocytokine production in type 2 diabetes mellitus rat model. Can J Physiol Pharmacol 96(12):1226\u20131231. https:\/\/doi.org\/10.1139\/cjpp-2017-0650","journal-title":"Can J Physiol Pharmacol"},{"issue":"2","key":"4456_CR103","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.apsb.2024.12.006","volume":"15","author":"C Dong","year":"2025","unstructured":"Dong C, Zhou B, Zhao B, Lin K, Tian Y, Zhang R et al (2025) GLP-1RAs attenuated obesity and reversed leptin resistance partly via activating the microbiome-derived inosine\/A2A pathway. Acta Pharm Sin B 15(2):1023\u20131038. https:\/\/doi.org\/10.1016\/j.apsb.2024.12.006","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"4456_CR104","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1038\/s41467-024-50660-y","volume":"15","author":"BK Jeong","year":"2024","unstructured":"Jeong BK, Choi WI, Choi W, Moon J, Lee WH, Choi C et al (2024) A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma. Nat Commun 15(1):6506. https:\/\/doi.org\/10.1038\/s41467-024-50660-y","journal-title":"Nat Commun"},{"issue":"5","key":"4456_CR105","doi-asserted-by":"publisher","first-page":"97136","DOI":"10.1371\/journal.pone.0097136","volume":"9","author":"S De Minicis","year":"2014","unstructured":"De Minicis S, Agostinelli L, Rychlicki C, Sorice GP, Saccomanno S, Candelaresi C et al (2014) HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS ONE 9(5):97136. https:\/\/doi.org\/10.1371\/journal.pone.0097136","journal-title":"PLoS ONE"},{"issue":"1","key":"4456_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42334-y","volume":"14","author":"K Soeda","year":"2023","unstructured":"Soeda K, Sasako T, Enooku K, Kubota N, Kobayashi N, Ikushima YM et al (2023) Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis. Nat Commun 14(1):6584. https:\/\/doi.org\/10.1038\/s41467-023-42334-y","journal-title":"Nat Commun"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04456-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04456-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04456-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:02:07Z","timestamp":1792731727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04456-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":106,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4456"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04456-1","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research does not directly involve patients; hence, ethical approval was deemed unnecessary.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FM is a consultant for AstraZeneca, Alfasigma, Boehringer Ingelheim, Gilead, Gore, Ipsem Madrigal, MSD\/EISAI, Novo Nordisk, Roche. FV is a consultant for Gore. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or performed in animal models.","order":3,"name":"Ethics","label":"Human and animal rights statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}